News and Events

Learn more about us, our science and our journey here.

Blogs

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Read more

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Read more

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Read more

Events

May 20, 2026
Helex presented a poster on mutation-agnostic, lipid nanoparticle (LNP) mediated gene editing therapy for PKD1-associated ADPKD at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, Boston, May 11-15, 2026.
Read more
Read more
February 20, 2026
Helex recognized as one of the Top 5 Startups at BioAsia 2026 by the Life Sciences & Pharma Government of Telangana,
Read more
Read more
September 24, 2025
Helex selected to present a poster on a lipid nanoparticle-driven, gene editing-based therapeutic to address PKD1-driven ADPKD at ASN Kidney Week, Houston, Texas, November 6–9, 2025
Read more
Read more
May 20, 2026
Helex presented a poster on mutation-agnostic, lipid nanoparticle (LNP) mediated gene editing therapy for PKD1-associated ADPKD at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, Boston, May 11-15, 2026.
Read more
Feb 20, 2026
Helex recognized as one of the Top 5 Startups at BioAsia 2026 by the Life Sciences & Pharma Government of Telangana,
Read more
Sep 24, 2025
Helex selected to present a poster on a lipid nanoparticle-driven, gene editing-based therapeutic to address PKD1-driven ADPKD at ASN Kidney Week, Houston, Texas, November 6–9, 2025
Read more
Aug 11, 2025
Helex to present its latest progress on a gene editing-based therapeutic for PKD1-driven ADPKD at the ESGCT Annual Meeting, Seville, Spain on October 8, 2025
Read more
Apr 28, 2025
Helex to present a Oral Presentation on its Lipid Nanoparticle-Mediated CRISPR-based Therapy for ADPKD in ASGCT 2025 taking place in New Orleans in May
Read more
Apr 28, 2025
Helex CEO, Poulami Chaudhuri, Ph D, selected to present Symposium talk on Harnessing Cell and Gene Therapies: New Frontiers in Kidney Treatment, scheduled for May 16, 2025
Read more
May 14, 2024
Helex presented with the Outstanding Poster Award at ASGCT2024 for the abstract on our therapeutic intervention for Autosomal Dominant Polycystic Kidney Disease!
Read more
May 3, 2024
Helex to present 3 posters at ASGCT 2024 in Baltimore covering our CRISPR Cas9 therapeutic approach for Autosomal Dominant Polycystic Kidney Disease and our drug design technology's guideRNA design and safety assessment capabilities
Read more
Jun 1, 2023
Helex CEO, Poulami Chaudhuri, Ph D, interviewed by Inside Precision Medicine magazine on Helex's approach to using the 3D genome structure and epigenome to guide development of gene edited therapies
Read more
May 16, 2023
Helex CEO, Poulami Chaudhuri, PhD featured on Forbes for being conferred the Science and Technology Pioneer 2023 award by the Cartier Women's Initiative
Read more
May 11, 2023
Helex to present two posters at ASGCT 2023 in Los Angeles on its proprietary cell & tissue specific editing technology and on its use of 3D genome structures and spatial organisations to better predict editing activity
Read more
May 10, 2023
Helex CEO awarded first place for the Science & Technology Pioneer Award 2023 by Cartier's Women Initiative!
Read more
Apr 10, 2023
Helex CEO, Poulami Chaudhuri, Ph D, named a Cartier's Women Initiative fellow
Read more
Apr 3, 2023
Helex awarded the XSEED 2023 prize for gene editing work in inherited retinal dystrophies
Read more
Dec 11, 2022
Helex to present its proprietary cell and tissue specific gene editing technology at ESGCT 2022 in Edinburgh
Read more
Mar 14, 2022
Helex to present its proprietary cell and tissue specific gene editing technology at Advanced Therapies in London
Read more
Jan 27, 2022
Helex Bio at IndieBio NY Class 3 Demo Day
Read more
May 20, 2026
Helex presented a poster on mutation-agnostic, lipid nanoparticle (LNP) mediated gene editing therapy for PKD1-associated ADPKD at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, Boston, May 11-15, 2026.
Read more
February 20, 2026
Helex recognized as one of the Top 5 Startups at BioAsia 2026 by the Life Sciences & Pharma Government of Telangana,
Read more
September 24, 2025
Helex selected to present a poster on a lipid nanoparticle-driven, gene editing-based therapeutic to address PKD1-driven ADPKD at ASN Kidney Week, Houston, Texas, November 6–9, 2025
Read more
August 11, 2025
Helex to present its latest progress on a gene editing-based therapeutic for PKD1-driven ADPKD at the ESGCT Annual Meeting, Seville, Spain on October 8, 2025
Read more
April 28, 2025
Helex to present a Oral Presentation on its Lipid Nanoparticle-Mediated CRISPR-based Therapy for ADPKD in ASGCT 2025 taking place in New Orleans in May
Read more
April 28, 2025
Helex CEO, Poulami Chaudhuri, Ph D, selected to present Symposium talk on Harnessing Cell and Gene Therapies: New Frontiers in Kidney Treatment, scheduled for May 16, 2025
Read more
May 14, 2024
Helex presented with the Outstanding Poster Award at ASGCT2024 for the abstract on our therapeutic intervention for Autosomal Dominant Polycystic Kidney Disease!
Read more
May 3, 2024
Helex to present 3 posters at ASGCT 2024 in Baltimore covering our CRISPR Cas9 therapeutic approach for Autosomal Dominant Polycystic Kidney Disease and our drug design technology's guideRNA design and safety assessment capabilities
Read more
June 1, 2023
Helex CEO, Poulami Chaudhuri, Ph D, interviewed by Inside Precision Medicine magazine on Helex's approach to using the 3D genome structure and epigenome to guide development of gene edited therapies
Read more
May 16, 2023
Helex CEO, Poulami Chaudhuri, PhD featured on Forbes for being conferred the Science and Technology Pioneer 2023 award by the Cartier Women's Initiative
Read more
May 11, 2023
Helex to present two posters at ASGCT 2023 in Los Angeles on its proprietary cell & tissue specific editing technology and on its use of 3D genome structures and spatial organisations to better predict editing activity
Read more
May 10, 2023
Helex CEO awarded first place for the Science & Technology Pioneer Award 2023 by Cartier's Women Initiative!
Read more

Press & publications

November 19, 2022
Incredibly proud that our co-founders Dr. Poulami Chaudhuri and Rohini Kalvakuntla have been listed as 100 women entrepreneurs building and shaping India.
Read more
Read more
June 24, 2022
Biotech startup Helex brings precision to gene editing
Read more
Read more
October 1, 2021
All the top 10 companies from IndieBio’s latest New York Cohort
Read more
Read more

Helex CEO Dr. Poulami Chaudhuri joined a panel on India’s deeptech ecosystem at the Rising Bharat Summit. July 2026

Read more

Helex CBO, Rohini Kalvakuntla, joined the panel 'Fundraising Insights: Perspectives from Female VCs and Founders' at Nucleate New York's Women in Bioinnovation & Leadership Forum

Read more

Helex won consecutive awards as a part of the Targeted genome Editor Delivery (TARGETED) Challenge organized by NIH for Targeted LNP Delivery and Tissue-Specific Gene Editing Apparatus for Safer In Vivo Gene Editing Therapeutics.

Read more
Revolutionizing genomic medicines
LEGAL
COMPANY
Privacy PolicyPressTerms & ConditionsContact
® 2025 Helex. All Rights Reserved | Web Design by Aquí